![Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. NPJ Precision Oncology, 2021](https://www.reactionbiology.com/wp-content/uploads/2023/07/Vincent-paper-thumbnail-1.png)
![Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. NPJ Precision Oncology, 2021](https://www.reactionbiology.com/wp-content/uploads/2023/07/Vincent-paper-thumbnail-1.png)
![Establishment of a methodological platform for the exploration of MCL1 inhibitors](https://www.reactionbiology.com/wp-content/uploads/2023/07/MCL1_Poster_thumbnail.png)
Establishment of a methodological platform for the exploration of MCL1 inhibitors
![A systems biology approach combining ProLiFiler™ and Cancer Data Miner for an enhanced preclinical characterization of the Wee1 inhibitor adavosertib](https://www.reactionbiology.com/wp-content/uploads/2023/07/ReactionBiology_ProLiFiler_Poster.png)
A systems biology approach combining ProLiFiler™ and Cancer Data Miner for an enhanced preclinical characterization of the Wee1 inhibitor adavosertib
![Analysis of the combinatorial anti-proliferative effect of inhibitors on a large panel of tumor cell lines.](https://www.reactionbiology.com/wp-content/uploads/2023/07/200601_Proli_combi_Poster.png)
Analysis of the combinatorial anti-proliferative effect of inhibitors on a large panel of tumor cell lines.
![Co-spheroid treatment with a MEK kinase inhibitor](https://www.reactionbiology.com/wp-content/uploads/2023/07/co-spheroid-poster.png)